RADIATION/NUCLEAR MEDICAL COUNTERMEASURE PRODUCT DEVELOPMENT SUPPORT

The National Institute of Allergy and Infectious Diseases has awarded an IDIQ contract titled “Radiation/Nuclear Medical Countermeasure Product Development Support” to advance the development of candidate medical countermeasures (MCMs), including biodosimetric approaches to determine radiation exposure. Research and development studies supported by this contract will advance candidate MCMs toward eventual FDA approval or licensure for acute radiation syndrome (ARS) or delayed effects of acute radiation exposure (DEARE). Candidate MCMs will enter the evaluation and development pathway at various stages, from early research to post marketing (for drugs or biologics that are already licensed or approved for other indications). The Contractor will collaborate with NIAID and, under the direction of NIAID, with organizations that have developed MCMs and with other federal authorities, including the Food and Drug Administration (FDA).